Septerna (SEPN) Income from Continuing Operations (2023 - 2026)
Septerna's quarterly Income from Continuing Operations came in at 8637000.0 in Q1 2026, up 59.78% year-on-year from 5405455.69 in Q1 2025, and up 19.57% quarter-over-quarter from 10738000.0 in Q4 2025.
Septerna has reported Income from Continuing Operations for 4 years, with the latest figure at 8637000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 59.78% year-over-year to 8637000.0; the trailing twelve-month figure through Mar 2026 stood at 36040000.0 (up 54.57% YoY), and the FY2025 full-year result was 48879000.0, up 31.92% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8637000.0, up from 10738000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8173000.0 in Q3 2025, with the low at 24838000.0 in Q2 2025.
- Average Income from Continuing Operations over 4 years is 14437818.18, with a median of 16659000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations sank 87.51% in 2024 and surged 139.82% in 2025.
- Tracing SEPN's Income from Continuing Operations over 4 years: stood at 18153000.0 in 2023, then dropped by 13.85% to 20668000.0 in 2024, then surged by 48.05% to 10738000.0 in 2025, then gained by 19.57% to 8637000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8637000.0 (Q1 2026), 10738000.0 (Q4 2025), and 8173000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.74 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.67 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.66 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -18.15 Mn |
| Sep 30, 2023 | -10.95 Mn |